Halogen In Acid Moiety Patents (Class 560/30)
  • Publication number: 20150148559
    Abstract: The invention provides new processes for making and purifying amino acid compounds, which are useful in the preparation of AKT inhibitors used in the treatment of diseases such as cancer, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 28, 2015
    Applicant: Genentech, Inc.
    Inventor: Travis Remarchuk
  • Publication number: 20150011773
    Abstract: This invention relates to novel compounds suitable for labeling by 18F and to the corresponding 18F labeled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by Positron Emission Tomography (PET).
    Type: Application
    Filed: April 30, 2012
    Publication date: January 8, 2015
    Applicant: PIRAMAL IMAGING SA
    Inventors: Mathias Berndt, Andre Muller, Heribert Schmitt-Willich, Timo Stellfeld, Georg Kettschau, Thomas Brumby, Keith Graham, Lutz Lehmann, Jorma Hassfeld, Martin Kruger
  • Publication number: 20140187558
    Abstract: The invention relates to the preparation of chiral compounds, in particular to the preparation of chiral compounds which may be used as intermediates for the preparation of anti-diabetic agents, preferably sitagliptin.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 3, 2014
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Zdenko Casar, Gaj Stavber
  • Publication number: 20140161839
    Abstract: The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(?O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(?O)—O—C(R8)(R9)—OC(?O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(?O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substi
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Applicant: PHARMALEADS
    Inventors: Bernard Roques, Herve Poras, Marie-Claude Fournie-Zaluski
  • Publication number: 20140066501
    Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.
    Type: Application
    Filed: November 11, 2013
    Publication date: March 6, 2014
    Applicant: XenoPort, Inc.
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
  • Patent number: 8598347
    Abstract: The present invention relates to an improved method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention allows reduction of production costs by reacting low cost reagents, improves yield and is adaptable for mass production.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: December 3, 2013
    Assignee: Dong-A Pharmaceutical. Co., Ltd
    Inventors: Woo Young Kwak, Heung Jae Kim, Jong Pil Min, Tae Hyun Yoon, Hyun Joo Shim, Moohi Yoo
  • Patent number: 8580850
    Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: November 12, 2013
    Assignee: XenoPort, Inc.
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
  • Patent number: 8524936
    Abstract: The present invention relates to a novel manufacturing process of pharmaceutically active compound of formula I used as oral anti-diabetic drug. Starting from L-aspartic acid derivate of formula IV the invention describes preparation of the chiral (R)-?-amino acid of formula II known as a precursor in the synthesis of Sitagliptin (formula I).
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: September 3, 2013
    Inventor: Milan Soukup
  • Publication number: 20130131371
    Abstract: There is provided a process for producing an amide compound having an excellent harmful arthropod-controlling activity and represented by the formula (3): wherein R1, R2 and R3 independently represent a C1-C6 alkyl group optionally substituted with at least one halogen atom etc., R4, R5, R6 and R7 independently represent a halogen atom etc.
    Type: Application
    Filed: January 18, 2013
    Publication date: May 23, 2013
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Sumitomo Chemical Company, Limited
  • Publication number: 20130041026
    Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.
    Type: Application
    Filed: August 10, 2012
    Publication date: February 14, 2013
    Applicant: XENOPORT, INC.
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
  • Patent number: 8367868
    Abstract: The present invention relates to a process for the synthesis of aryloxypropylamine and heteroaryloxypropylamine of formula I: where: A is aryl or heteroaryl, where the aryl is preferably a phenyl, optionally substituted, selected from benzyl and tolyl and the heteroaryl is preferably thiophenyl; Y is an aryl, preferably phenyl, a substituted phenyl or a naphthyl, where the substituted phenyl is preferably selected from tolyl, trihalomethyltolyl and alkoxytolyl, starting from a suitable amino alcohol of formula II:
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: February 5, 2013
    Assignee: Archimica S.r.l.
    Inventors: Giorgio Bertolini, Barbara Verzola, Domenico Vergani
  • Patent number: 8299291
    Abstract: The present disclosure relates to methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs and to intermediates used in the methods.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: October 30, 2012
    Assignees: XenoPort, Inc., Glaxo Group Limited
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Peng Liu, Qunying Dai, Hao Yin
  • Publication number: 20120184745
    Abstract: The present invention is an improved method for the preparation of 4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester, compound of formula I. The invention is directed to a method of synthesis for the compound of formula I in three steps, comprising formation of 5-((tert-butoxycarbonyl)aminomethyl)-2-fluorobenzeneboronic acid (compound 11), reaction of compound 11 under Suzuki coupling conditions to yield (4-fluoro-2-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester and selective hydrogenation of the aforementioned product under hydrogenation conditions yields compound I. The invention is also directed to the intermediates 5-((tert-butoxycarbonyl)amino-methyl)-2-fluorobenzeneboronic acid (compound 11), and (4-fluoro-2-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester (compound 13).
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: SANOFI-AVENTIS U.S. LLC
    Inventors: Nakyen CHOY, John J. SHAY, JR., Adam W. SLEDESKI
  • Patent number: 8222314
    Abstract: Urethane acrylates of the general Formula (I), corresponding salts, solvates or solvates of a salt thereof: wherein R1, R2, R3, R4 and R5 each independently represent a substituent selected from the group consisting of hydrogen, halogens, C1-6-alkyls, trifluoromethyl, C1-6-alkylthios, C1-6-alkylselenos, C1-6-alkyltelluros, and nitro groups, with the proviso that at least one of R1, R2, R3, R4 and R5 is not hydrogen; R6 and R7 each independently represent a substituent selected from the group consisting of hydrogen and C1-6-alkyls; and A represents a saturated or unsaturated or linear or branched C1-6-alkyl radical or a polyalkylene oxide radical having 2-6 ethylene oxide or propylene oxide units; processes for producing and methods of using the same.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: July 17, 2012
    Assignee: Bayer MaterialScience AG
    Inventors: Thomas Roelle, Friedrich-Karl Bruder, Thomas Fäcke, Marc-Stephan Weiser, Dennis Hönel
  • Publication number: 20120178666
    Abstract: Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.
    Type: Application
    Filed: September 15, 2010
    Publication date: July 12, 2012
    Applicant: SHIRE LLC
    Inventors: Richard Franklin, Robert G. Tyson, Bernard T. Golding, Rhys Whomsley
  • Publication number: 20120178957
    Abstract: The present invention relates to Sitagliptin intermediate and preparation method and use thereof. The method comprises reacting compound of formula (II) and trifluorobromobenzene with a Grignard reagent by a Grignard reaction to obtain a compound of formula (I). Compound of formula (I) is a new intermediate compound for the synthesis of Sitagliptin. Compound of formula (I) can be easily used for preparing another important intermediate compound of formula (V) for the synthesis of Sitagliptin.
    Type: Application
    Filed: September 25, 2010
    Publication date: July 12, 2012
    Inventors: Guoliang Zhu, Jian Zhang, Lljun Yang, Qingdan Yao, Jie Ying
  • Publication number: 20120123144
    Abstract: The present invention relates to a novel manufacturing process of pharmaceutically active compound of formula I used as oral anti-diabetic drug. Starting from L-aspartic acid derivate of formula IV the invention describes preparation of the chiral (R)-?-amino acid of formula II known as a precursor in the synthesis of Sitagliptin (formula I).
    Type: Application
    Filed: May 18, 2011
    Publication date: May 17, 2012
    Applicant: Drug Process Licensing Associates, LLC
    Inventor: Milan Soukup
  • Patent number: 8153844
    Abstract: Disclosed is a method for preparing a compound of Formula 1 by contacting compound of Formula 2 with R1—NH2 in the presence of a carboxylic acid and a method for preparing a compound of Formula 2 by contacting a compound of Formula 4 with phosphorus tribromide. wherein R1 is H, C1-C4 alkyl, cyclopropyl, cyclopropylmethyl or methylcyclopropyl; R2 is CH3 or Cl; R3 is C1-C6 alkyl or C3-C6 alkenyl, each optionally substituted with up to 3 halogen and up to 1 phenyl; and X is Cl or Br. Also disclosed is a method for preparing a compound of Formula 5 wherein R4, R5, R6 and Z are as defined in the disclosure, using a compound of Formula 1 that is characterized by preparing the compound of Formula 1 by the method above.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: April 10, 2012
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Richard F. Davis, Rafael Shapiro, Eric G. Taylor
  • Publication number: 20120016125
    Abstract: The present invention relates to an improved method for preparing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention is able to reduce preparation costs by using low cost reagents on reaction and is able to be used in mass production by improving yield.
    Type: Application
    Filed: March 30, 2010
    Publication date: January 19, 2012
    Applicant: DONG-A PHARMACEUTICAL. CO., LTD
    Inventors: Woo Young Kwak, Heung Jae Kim, Jong Pil Min, Tae Hyun Yoon, Moohi Yoo, Geun Gho Lim, Sun Ki Chang
  • Publication number: 20120016126
    Abstract: The present invention relates to an improved method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention allows reduction of production costs by reacting low cost reagents, improves yield and is adaptable for mass production.
    Type: Application
    Filed: March 30, 2010
    Publication date: January 19, 2012
    Applicant: DONG-A PHARMACEUTICAL. CO., LTD
    Inventors: Woo Young Kwak, Heung Jae Kim, Jong Pil Min, Tae Hyun Yoon, Hyun Joo Shim, Moohi Yoo
  • Publication number: 20120010425
    Abstract: Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
    Type: Application
    Filed: August 11, 2011
    Publication date: January 12, 2012
    Applicant: XENOPORT, INC.
    Inventors: Mark A. Gallop, Xuedong Dai, Randall A. Scheuerman, Stephen P. Raillard, Suresh K. Manthati, Fenmei Yao, Thu Phan, Maria Ludwikow, Ge Peng, Seema Bhat
  • Patent number: 8058468
    Abstract: The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds around the lead compound (3,4-dichloro-phenyl)-carbamic acid 2-isobutoxycarbonylamino-1-methyl-ethyl ester, which are especially useful for combating infections with gram-positive bacteria and especially MRSA.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 15, 2011
    Assignee: Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek TNO
    Inventors: Frank Henri Johan Schuren, Henricus Matheus Wilhelmus Maria Thijssen, Roy Christiaan Montijn
  • Publication number: 20110190527
    Abstract: The present invention provides a method for producing an optically active N-(halopropyl)amino acid derivative, wherein the method comprises the steps of obtaining a compound represented by formula (III) by reacting an optically active alanine ester represented by formula (I) or a salt thereof (hereinafter sometimes simply referred to as an “alanine ester”) with a halogenated propane represented by formula (II); and obtaining an optically active N-(halopropyl)amino acid derivative represented by formula (IV) by introducing a protecting group onto the nitrogen atom of the compound represented by formula (III). The present invention provides a method for efficiently producing an optically active N-(halopropyl)amino acid derivative.
    Type: Application
    Filed: May 19, 2008
    Publication date: August 4, 2011
    Applicant: Nagase & Co., Ltd.
    Inventors: Jun Matsumoto, Toru Inoue
  • Publication number: 20110104057
    Abstract: What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
    Type: Application
    Filed: May 13, 2009
    Publication date: May 5, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ludger Dinkelborg, Keith Graham, Mathias Berndt, Norman Koglin, Heribert Schmitt-Willich, Matthias Friebe, Lutz Lehmann
  • Patent number: 7902401
    Abstract: Compounds of Formula I are useful in the treatment of epilepsy, neuropathic pain, acute and chronic inflammatory pain, migraine, tardive dyskinesia and other related CNS disorders. wherein: A and R1 to R8 are defined in the specification.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: March 8, 2011
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Guy A. Higgins, Methvin Issac, Abdelmalik Slassi, Tao Xin
  • Publication number: 20110021571
    Abstract: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.
    Type: Application
    Filed: September 16, 2010
    Publication date: January 27, 2011
    Applicant: XenoPort, Inc.
    Inventors: Mark A. Gallop, Fenmei Yao, Maria J. Ludwikow, Thu Phan, Ge Peng
  • Patent number: 7790836
    Abstract: Disclosed herein is a novel functional diamine compound having a dendron structure, polyamic acid which is produced using functional diamine, aromatic cyclic diamine, aliphatic cyclic acid dianhydride, and aromatic cyclic acid dianhydride, polyimide which is produced by imidizing polyamic acid, and an LC alignment film produced using polyimide. Even if the diamine compound is used in a small amount, it is possible to realize a high pretilt angle, thus the pretilt angle is easily controlled. Therefore, it can be used to produce an LC alignment film using a twisted nematic (TN) mode, in which the pretilt angle of liquid crystal is low, and a vertically aligned (VA) mode, which requires a high pretilt angle of about 90°.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: September 7, 2010
    Assignee: Cheil Industries Inc.
    Inventors: Jae Min Oh, Moo Young Lee, Bum Jin Lee, O Bum Kwon, Won Seok Dong, Yusuke Tsuda
  • Publication number: 20100105942
    Abstract: The present invention relates to a process for the synthesis of aryloxypropylamine and heteroaryloxypropylamine of formula I: where: A is aryl or heteroaryl, where the aryl is preferably a phenyl, optionally substituted, selected from benzyl and tolyl and the heteroaryl is preferably thiophenyl; Y is an aryl, preferably phenyl, a substituted phenyl or a naphthyl, where the substituted phenyl is preferably selected from tolyl, trihalomethyltolyl and alkoxytolyl, starting from a suitable amino alcohol of formula II:
    Type: Application
    Filed: October 4, 2007
    Publication date: April 29, 2010
    Inventors: Giorgio Bertolini, Barbara Verzola, Domenico Vergani
  • Publication number: 20100099898
    Abstract: Disclosed are intermediates and processes for preparing epoxides of the formula: where R and PROT are defined herein. These epoxides are useful as intermediates in the production of biologically active compounds, i.e., in the production of pharmaceutical agents.
    Type: Application
    Filed: December 23, 2009
    Publication date: April 22, 2010
    Inventor: Michael R. Reeder
  • Publication number: 20100087667
    Abstract: The present disclosure relates to methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs and to intermediates used in the methods.
    Type: Application
    Filed: August 7, 2009
    Publication date: April 8, 2010
    Applicants: XenoPort, Inc., Glaxo Group Limited
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Peng Liu, Qunying Dai, Hao Yin
  • Publication number: 20100036013
    Abstract: Urethane acrylates of the general Formula (I), corresponding salts, solvates or solvates of a salt thereof: wherein R1, R2, R3, R4 and R5 each independently represent a substituent selected from the group consisting of hydrogen, halogens, C1-6-alkyls, trifluoromethyl, C1-6-alkylthios, C1-6-alkylselenos, C1-6-alkyltelluros, and nitro groups, with the proviso that at least one of R1, R2, R3, R4 and R5 is not hydrogen; R6 and R7 each independently represent a substituent selected from the group consisting of hydrogen and C1-6-alkyls; and A represents a saturated or unsaturated or linear or branched C1-6-alkyl radical or a polyalkylene oxide radical having 2-6 ethylene oxide or propylene oxide units; processes for producing and methods of using the same.
    Type: Application
    Filed: August 7, 2009
    Publication date: February 11, 2010
    Applicant: Bayer MaterialScience AG
    Inventors: Thomas Roelle, Friedrich-Karl Bruder, Thomas Fäcke, Marc-Stephan Weiser, Dennis Hönel
  • Patent number: 7563938
    Abstract: The present invention is directed to novel alkylated aromatic compositions, zeolite catalyst compositions and processes for making the same. The catalyst compositions comprise zeolite Y and mordenite zeolite having a controlled macropore structure. The present invention is also directed to the preparation of the catalyst compositions and their use in the preparation of novel alkylated aromatic compositions. The catalyst compositions of the present invention exhibit reduced deactivation rates during the alkylation process, thereby increasing the life of the catalysts.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: July 21, 2009
    Assignees: Chevron Oronite Company LLC, Chevron Oronite S.A.
    Inventors: Curt B. Campbell, Thomas V. Harris, Pierre Tequi, Jean-Louis Le Coent
  • Patent number: 7563937
    Abstract: The present invention is directed to a zeolite Y catalyst having a controlled macropore structure. The present invention is also directed to a zeolite Y catalyst composite and a process for preparing the catalyst composite. The catalyst composite exhibits reduced deactivation rates during the alkylation process, thereby increasing the life of the catalyst. The present invention is also directed to processes for the preparation of carbonated, overbased aromatic sulfonates, which processes comprise alkylation, carbonation of aromatic hydrocarbons with one or more olefins.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: July 21, 2009
    Assignees: Chevron Oronite Company LLC, Chevron Oronite S.A.
    Inventors: Thomas V. Harris, Curt B. Campbell, Paul J. Marcatntonio, Pierre Tequi, Jean-Louis Le Coent
  • Patent number: 7041863
    Abstract: The present invention is directed to a zeolite Y catalyst having a controlled macropore structure. The present invention is also directed to a zeolite Y catalyst composite and a process for preparing the catalyst composite. The catalyst composite exhibits reduced deactivation rates during the alkylation process, thereby increasing the life of the catalyst. The present invention is also directed to processes for the preparation of carbonated, overbased aromatic sulfonates, which processes comprise alkylation, carbonation of aromatic hydrocarbons with one or more olefins.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: May 9, 2006
    Assignees: Chevron Oronite Company LLC, Chevron Oronite S.A.
    Inventors: Thomas V. Harris, Curt B. Campbell, Paul J. Marcantonio, Pierre Tequi, Jean-Louis Le Coent
  • Patent number: 7026515
    Abstract: A readily available and inexpensive natural ?-amino acid is converted into a compound represented by formula (1), which is then reacted with an organometallic reagent represented by formula (2) to give an optically active 5-hydroxyoxazolidine represented by formula (3), which is then treated with an acid to provide an optically active aminoketone represented by formula (4). The product is then converted into an optically active aminoalcohol represented by formula (5) or (6) by, for example reduction.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: April 11, 2006
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Hidetoshi Tsunoda, Kunio Okumura, Kengo Otsuka
  • Patent number: 6972292
    Abstract: The present invention relates to certain substituted polyketides of formula I, wherein A, B, C, D, E, F and m are as defined herein, pharmaceutical compositions containing said compounds, and the use of said compounds in treating tumors.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: December 6, 2005
    Assignee: Novartis AG
    Inventors: Frederick Ray Kinder, Jr., Kenneth W. Bair, Timothy M. Ramsey, Michael L. Sabio
  • Patent number: 6972340
    Abstract: Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: December 6, 2005
    Assignee: Abbott Laboratories
    Inventors: Gang Liu, Bruce G. Szczepankiewicz, Zhonghua Pei, Zhili Xin, David A. Janowick
  • Patent number: 6919380
    Abstract: Derivatives of C2-substituted indan-1-ol compounds of formula I: its physiologically acceptable salts, and its physiologically functional derivatives for the prophylaxis or treatment of obesity are disclosed herein. Compositions comprising the same, methods for preparing the instant compounds, and methods for reducing weight in mammals and for the prophylaxis or treatment of obesity are also described.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: July 19, 2005
    Assignee: Aventis Pharma Deutschland GmbH.
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Patent number: 6894185
    Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: May 17, 2005
    Assignee: Allós Therapeutics, Inc.
    Inventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
  • Patent number: 6831102
    Abstract: New thyroid receptor ligands are provided which have the general formula I: wherein R1 is halogen, trifluoromethyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted C3-7 cycloalkyl; R2 and R3 are each independently hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted C3-6 cycloalkyl, wherein at least one of R2 and R3 is other than hydrogen; R4 is a carboxylic acid selected from the group consisting of (CH2)nCOOH, (CH)2COOH, NHCO(CH2)nCOOH, CONH(CH2)nCOOH and NH(CH2)mCOOH; n is an integer from 0 to 4; and m is an integer from 1 to 4. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: December 14, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jon J. Hangeland
  • Patent number: 6812257
    Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Patent number: 6806365
    Abstract: Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: October 19, 2004
    Assignee: Hoffmann-La Rocher Inc.
    Inventors: Li Chen, Robert William Guthrie, Tai-Nang Huang, Achytharao Sidduri, Jefferson Wright Tilley, Kenneth Gregory Hull
  • Publication number: 20040110831
    Abstract: The invention relates to the compounds of general formula (I), that are present with respect to R1 as racemates as well as L- or D-configured compounds and as E/Z mixtures as well as E or Z isomers and in which the various symbols are defined as in the description and the claims, as well as to the salts thereof, for use as therapeutic agents and for diagnostic purposes. The inventive compounds can be processed to medicaments or to diagnostic agents that are used for the diagnosis, therapy and prevention of urokinase- or urokinase-receptor associated diseases, for example for the treatment of tumors. The compounds are highly efficient in inhibiting growth and/or spread of malign tumors, for example tumor spread of pancreatic cancer, tumor growth of breast cancer and the formation of tumor metastases. The compounds of formula (I) and the salts thereof can be produced by conventional methods.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 10, 2004
    Inventor: Hugo Ziegler
  • Patent number: 6667413
    Abstract: The present invention relates to an uracil compound of the formula [I]: wherein W represents oxygen, sulfur, imino or C1 to C3 alkylimino; Y represents oxygen, sulfur, imino or C1 to C3 alkylimino; R1 represents C1 to C3 alkyl or C1 to C3 haloalkyl; R2 represents C1 to C3 alkyl; R4 represents hydrogen or methyl; R5 represents C1 to C6 alkyl, C1 to C6 haloalkyl, or the like; X1 represents halogen, cyano or nitro; X2 represents hydrogen or halogen; and each of X3 and X4 independently represents hydrogen, halogen, C1 to C6 alkyl, or the like. The present compound has an excellent herbicidal activity.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: December 23, 2003
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Yoshitomo Tohyama, Yuzuru Sanemitsu, Tomohiko Gotou
  • Patent number: 6638977
    Abstract: Compounds and pharmaceutical compositions useful as plasminogen activator inhibitor (PAI) antagonists are provided. In particular, methods of antagonizing PAI with substituted and unsubstituted aryl and heteroaryl ethers and thioethers are provided.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: October 28, 2003
    Assignee: Corvas International, Inc.
    Inventors: Edwin L. Madison, Terence K. Brunck, Joseph Edward Semple, Marguerita Lim-Wilby, Kent E. Pryor
  • Patent number: 6620961
    Abstract: Biarylalkylenecarbamic acid derivative represented by general formula (I): [wherein Q is a phenyl group which may be substituted or the like, X is a halogen atom, a (C1-C6) alkyl group or the like, n is 0 or an integer of from 1 to 4, R1 is a (C1-C6) alkyl group or the like, R2 is a hydrogen atom, a (C1-C6) alkyl group or the like, A is a (C1-C7) alkylene group which may be branched, and G is an oxygen atom, a sulfur atom or a group —NR— (wherein R3 is a hydrogen atom or a (C1-C4) alkyl group)] and agricultural and horticultural fungicides. The agricultural and horticultural fungicides of the present invention are useful as agricultural and horticultural fungicides because they have high preventive effects on cucumber downy mildew, apple scab, wheat powdery mildew, rice blast, cucumber gray mold and rice sheath blight without damaging crops, and are excellent in residual effectiveness and rain-resistance.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: September 16, 2003
    Assignees: Kumiai Chemical Industry Co., Ltd., Ihara Chemical Industry Co. Ltd.
    Inventors: Kazuhiro Ikegaya, Masami Ozaki, Takahiro Kawashima, Ichiro Miura, Norimichi Muramatsu
  • Patent number: 6570034
    Abstract: The present invention relates to a novel blocked phenylenediamine developer useful, in reactive association, for enabling, on development, a non-magenta color, for example a cyan color, from a dye-forming coupler. In one embodiment, the developer has the property that the dye color formed with the coupler is distinctly different from the color formed by the same coupler with an oxidized form of the conventional developer 4-(N-ethyl-N-2-hydroxyethyl)-2-methylphenylenediamine. The invention is also directed to a light-sensitive silver-halide color photographic element comprising the blocked developing agent according to the present invention.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: May 27, 2003
    Assignee: Eastman Kodak Company
    Inventors: Richard P. Szajewski, Lyn M. Irving
  • Patent number: 6486342
    Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: November 26, 2002
    Assignee: Virginia Commonwealth University
    Inventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
  • Patent number: 6486341
    Abstract: Compounds of formula (I) wherein R1 is C1-C4-alkyl or cyclopropyl; R2 is C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkinyl; or C1-C6-alkyl substituted by 1 to 5 fluorine atoms; R3 is C1-C6-alkyl, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkoxy, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkinyl, C2-C6-alkinyloxy, C1-C6-alkoxycarbonyl, CN, or aryl, heteroaryl, heterocyclyl, aryloxy, heteroaryloxy or heterocyclyloxy, whereby the above-mentioned groups may be substituted by identical of different substituents, R5 signifies hydrogen or methyl; R6 and R7 are C1-C4-alkyl; have microbicidal, insecticidal and acaricidal activity and may be used for the control of pests and plant-pathogenic fungi in agriculture, horticulture and in the field of hygiene.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: November 26, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventor: Hugo Ziegler
  • Patent number: 6420603
    Abstract: A novel process for the preparation of N,N′-bis[2,3-dihydroxypropyl]-5-[(hydroxyacetyl) methylamino]-2,4,6-triiodo-1, 3-benzenedi carboxamide of formula (I), commonly known as lomeprol, a novel non-ionic contrast agent which shows very good safety and contrast effectiveness.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: July 16, 2002
    Assignee: Bracco International B.V.
    Inventors: Laura Alessandroni, Patrizia Ambrosetti, Maria Argese, Renato Geremia, Enrico Moretti, Vittorio Valle, Giorgio Ripa, Marcella Murru